HopeStage
Back to all studies
RecruitingNCT06860958

Roflumilast added to antidepressants for major depression

About this titleRead the official source — NCT06860958
Medication studyAges 18–65Egypt
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 65 years.

Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: March 1, 2025
Recruitment status
Recruiting
Enrollment listed in the registry
60
Sponsor
Tanta University
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
Egypt
Age range
From 18 Years to 65 Years
Official registry ID
NCT06860958
Official title
Show the full official title

Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients

Recruitment & locations

Currently recruiting

Tanta

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Tanta University, a university.

Does this study involve medication?

Yes. The study involves medication, including Fluoxetine, Roflumilast and Placebo.

Who can participate?

Listed age limits: 18 years to 65 years.

Is this study still recruiting?

The registry lists this study as recruiting.

Want to explore more studies?

Explore studies